Zwicker Jeffrey I, Furie Barbara C, Furie Bruce
Center for Hemostasis and Thrombosis Research, Beth Israel Deaconess Medical Center and the Department of Medicine, Harvard Medical School, Boston, MA 02115, United States.
Crit Rev Oncol Hematol. 2007 May;62(2):126-36. doi: 10.1016/j.critrevonc.2007.01.001. Epub 2007 Feb 12.
There is strong evidence linking venous thromboembolic events and malignancy. Laboratory markers of coagulation activation such as thrombin-antithrombin complex or prothrombin fragments 1+2 support the premise that malignancy is a hypercoagulable state. Inflammatory cytokines (e.g. tumor necrosis factor and interferon-gamma), coagulation proteins (e.g. tissue factor and factor VIII), and procoagulant microparticles may be elevated in patients with malignancy. However, the molecular basis for cancer associated thrombosis remains unknown and the relative contribution of chemotherapeutics, tumor cells, endothelium, and circulating procoagulants in promoting thrombus formation continues to be investigated.
有充分证据表明静脉血栓栓塞事件与恶性肿瘤之间存在关联。凝血活化的实验室标志物，如凝血酶 - 抗凝血酶复合物或凝血酶原片段1 + 2，支持恶性肿瘤是一种高凝状态的前提。炎症细胞因子（如肿瘤坏死因子和干扰素 - γ）、凝血蛋白（如组织因子和因子VIII）以及促凝微粒在恶性肿瘤患者中可能会升高。然而，癌症相关血栓形成的分子基础仍然未知，化疗药物、肿瘤细胞、内皮细胞和循环促凝剂在促进血栓形成中的相对作用仍在继续研究。
